Vanishing Act: How New Tech Zaps Hidden Heart Arrhythmias
"Innovative software helps doctors pinpoint and eliminate elusive PVCs, even under anesthesia, offering new hope for heart rhythm control."
Frequent premature ventricular contractions (PVCs) and non-sustained ventricular tachycardia can negatively impact heart function, leading to palpitations, dizziness, and, in rare cases, syncope. When intervention is necessary, ablation—a procedure to eliminate the source of these arrhythmias—is often performed under general anesthesia or conscious sedation, especially in children.
However, anesthesia presents a significant challenge: it can suppress spontaneous ventricular ectopy, making it difficult to locate the precise origin of the arrhythmia. Traditional methods rely on activation-time mapping and subjective comparison of paced and targeted QRS morphology, which can be unreliable when arrhythmias are infrequent.
But what if there was a way to overcome the limitations imposed by anesthesia? Recent research explores a quantitative approach using PaSo software (Carto 3, Biosense-Webster) to enhance the accuracy of pace-mapping, even when spontaneous arrhythmias are scarce. This article delves into this innovative technique and its potential to improve the success of PVC ablation.
Real-World Ablation Outcomes
A 2024 real-world study reported acute success rates of 94.2% for ventricular tachycardia ablation and 92.2% for premature ventricular contraction ablation. In its PVC group, complete success was achieved in 36 of 51 patients, or 70.6%. Catheter ablation is described as the most efficacious approach for eliminating PVCs, although it can involve greater upfront risk.
Mapping, Medicines, and Selection
Contemporary PVC ablation involves evaluating electrocardiographic features, mapping the PVC, and selecting an ablation strategy based on the arrhythmia's characteristics and anatomical location. Mayo Clinic notes that ablation may be considered when frequent PVCs persist despite lifestyle changes and medicines or when they cause serious problems. A key limitation is the absence of standardized criteria for selecting patients with structural heart disease and frequent PVCs.
From DC Shocks to PVC Ablation
The first catheter ablation in humans was performed by Dr. Melvin Scheinman in 1981 using high-energy direct-current shocks. Later work on PVC ablation established principles intended to make the procedure safe and effective. PVCs are extra beats originating in the ventricles; although often benign, frequent PVCs can cause symptoms and may become a treatment target.
Pinpointing the Problem: How Does the Technology Work?
The study, conducted at Children's National Health System in Washington, DC, involved 24 patients (26 procedures) undergoing ablation for frequent ventricular arrhythmias. When activation-time (AT) mapping was limited due to infrequent arrhythmias, pace-mapping was performed using the PaSo software. This software quantitatively compares the morphology of paced QRS complexes to the targeted PVC morphology, aiding in the localization of the arrhythmia's origin.
- Initial Assessment: Patients were monitored before anesthesia to identify any naturally occurring arrhythmias.
- Anesthesia Management: Anesthesia was administered based on patient maturity and preference, ranging from general anesthesia to conscious sedation.
- Electrophysiology Study: Access to the heart was gained through femoral veins and arteries. Catheters were used to map the heart and identify the PVC origin.
- Pace-Mapping with PaSo: When AT mapping was insufficient, pace-mapping was performed, with the PaSo software providing a quantitative assessment of QRS morphology match.
- Ablation: Once the optimal site was identified (typically with >92% similarity), radiofrequency or cryoablation was used to eliminate the arrhythmia.
Evidence Favoring Ablation
A 2023 review comparing catheter ablation with antiarrhythmic drug therapy for PVCs found that catheter ablation appeared superior for reducing PVC recurrence, frequency, and burden. The review therefore points toward a stronger rhythm-control effect for ablation than for antiarrhythmic drugs. A 2025 outcomes report also found that radiofrequency ablation was associated with substantial reductions in antiarrhythmic-drug use, which had been 58% before the procedure.
When Ablation Falls Short
Repeat ablation is not uniformly successful: a 2025 study reported acute success in 59% of patients whose first ablation had failed, with 75% of those acutely successful patients showing long-term success. In epicardial radiofrequency procedures, reported reasons for failure or limited ablation included unsuccessful epicardial access in 6% of cases and failure to identify an epicardial target in 15%. These findings show that repeat procedures and difficult targets can limit otherwise promising treatment.
Ablation Versus Drug Therapy
Comparative analyses report that catheter radiofrequency ablation appears more effective than antiarrhythmic drugs for reducing PVC frequency and normalizing left-ventricular ejection fraction. A separate review likewise found catheter ablation superior to antiarrhythmic drugs for PVC recurrence, frequency, and burden. The evidence therefore favors ablation for these measured outcomes, although one analysis noted that a randomized controlled clinical trial was still needed.
The Future of Heart Rhythm Treatment
This research offers a promising solution to a common challenge in arrhythmia ablation: the suppression of spontaneous arrhythmias by anesthesia. By using quantitative morphology-matching software, doctors can more accurately locate and eliminate PVCs, even when they are 'vanishing' due to anesthesia.
Consensus-Guided Care
The 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement provides guidance on selecting patients for ventricular-arrhythmia ablation. It also addresses how to perform procedures safely and effectively, along with follow-up and adjunctive care. A live PVC-ablation case led by Dr. Francis Marchlinski illustrates how experienced electrophysiology teams use real-time procedural observation and expert discussion.
A Growing Treatment Landscape
One market forecast projects that the cardiac ablation market will grow from USD 6.72 billion in 2026 to USD 22.27 billion by 2035. Another forecast expects the global cardiac ablation market to expand at an approximate 13% compound annual growth rate through 2030. Clinical outcomes remain an important benchmark: a 2024 real-world study reported a 92.2% acute success rate for PVC ablation, while complete success occurred in 70.6% of its patients.
Uneven Access and Uncertainty
The future of arrhythmia treatment will likely depend not only on technical advances but also on consistent patient selection, procedural expertise, and follow-up. Access to specialized electrophysiology care may vary between health systems, while the benefits and risks of newer approaches can remain uncertain as evidence develops. These broader constraints can shape who receives treatment and how reliably its results are reproduced.
New Tools for Difficult Arrhythmias
Recent human case reports have expanded interest in pulsed-field ablation for ventricular arrhythmias, including PVCs and ventricular tachycardia. A 2025 case report described successful pulsed-field ablation of PVCs originating from the papillary muscle, attributing the result to more consistent contact and improved lesion formation. Separately, a 2026 real-world cohort study reported that post-pulmonary-vein-isolation increases in PVC burden occurred in a relatively small proportion of patients.
The implications of this technology extend beyond improved success rates. It also opens the door for:
<ul> <li><b>Reduced Procedure Times:</b> More accurate mapping could lead to quicker identification of the arrhythmia source, shortening procedure times.</li> <li><b>Improved Patient Outcomes:</b> By overcoming the limitations of anesthesia, more patients could benefit from successful ablation.</li> <li><b>Wider Applicability:</b> The technique could be particularly valuable in pediatric patients, where anesthesia is often necessary.</li> </ul>